Substances addressing the opioid system are widely used pharmaceuticals. Agonists (narcotic analgesics) are used for the treatment of chronic pain, whereas antagonists are generally effective in the treatment of addictive disorders, including substance abuse (opiate, alcohol, amphetamine) and non-substance, i.e. behavioral addictions such as gaming, gambling and over-eating. The proposed program project will use structural, biophysical, biochemical, and pharmacological approaches to understand ligand binding properties of all opioid receptors (p-, 6, K (MOR, DOR, KOR), and the nociceptin/orphanin FQ peptide receptor (NOP)) and to define the structural basis for molecular recognition and activation. The three overall aims are (1): Understand opioid receptor molecular recognition and functional selectivity using X-ray crystallography to determine structures of ligand-receptor complexes and NMR to understand dynamic behavior. (2) Understand the molecular mechanisms for functional and pharmacological selectivity for the four opioid receptors using computational approaches, and (3) Understand ligand-directed signaling (G- protein-, arrestin-, JNK-dependent) and its relevance in mediating opioid receptor action. Management and administration of the project will be carried out by the Management and Administration Core. Its main responsibilities include (1) Overall management of all project to ensure progress, (2) Prioritization of studies, (3) Assembly of a Scientific Advisory Board, (4) Preparation of required progress reports, (5) Establishment and facilitation of communication routes within the POI as well as with external stakeholders (e.g. SAB, NIH), and (6) Assurance ofthe high quality of studies and results.

Public Health Relevance

Understanding the binding landscape of opioid receptors is essential in developing new therapeutics needed to address the growing problem of prescription drug addiction as well as at producing highly selective drugs forthe treatment of wide ranging conditions including pain, anxiety, depression, and physical dependence.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Program Projects (P01)
Project #
7P01DA035764-02
Application #
8828155
Study Section
Special Emphasis Panel (ZRG1-BCMB-S)
Project Start
Project End
Budget Start
2015-04-01
Budget End
2016-03-31
Support Year
2
Fiscal Year
2015
Total Cost
$121,419
Indirect Cost
$44,729
Name
University of Southern California
Department
Type
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Che, Tao; Majumdar, Susruta; Zaidi, Saheem A et al. (2018) Structure of the Nanobody-Stabilized Active State of the Kappa Opioid Receptor. Cell 172:55-67.e15
Vickery, Owen N; Carvalheda, Catarina A; Zaidi, Saheem A et al. (2018) Intracellular Transfer of Na+ in an Active-State G-Protein-Coupled Receptor. Structure 26:171-180.e2
Popov, Petr; Peng, Yao; Shen, Ling et al. (2018) Computational design of thermostabilizing point mutations for G protein-coupled receptors. Elife 7:
Schattauer, Selena S; Land, Benjamin B; Reichard, Kathryn L et al. (2017) Peroxiredoxin 6 mediates G?i protein-coupled receptor inactivation by cJun kinase. Nat Commun 8:743
Roach, Jeremy J; Sasano, Yusuke; Schmid, Cullen L et al. (2017) Dynamic Strategic Bond Analysis Yields a Ten-Step Synthesis of 20-nor-Salvinorin A, a Potent ?-OR Agonist. ACS Cent Sci 3:1329-1336
Schattauer, Selena S; Kuhar, Jamie R; Song, Allisa et al. (2017) Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor. Cell Signal 32:59-65
Wacker, Daniel; Stevens, Raymond C; Roth, Bryan L (2017) How Ligands Illuminate GPCR Molecular Pharmacology. Cell 170:414-427
Huang, Xi-Ping; Che, Tao; Mangano, Thomas J et al. (2017) Fentanyl-related designer drugs W-18 and W-15 lack appreciable opioid activity in vitro and in vivo. JCI Insight 2:
Zheng, Zhong; Huang, Xi-Ping; Mangano, Thomas J et al. (2017) Structure-Based Discovery of New Antagonist and Biased Agonist Chemotypes for the Kappa Opioid Receptor. J Med Chem 60:3070-3081
Lansu, Katherine; Karpiak, Joel; Liu, Jing et al. (2017) In silico design of novel probes for the atypical opioid receptor MRGPRX2. Nat Chem Biol 13:529-536

Showing the most recent 10 out of 25 publications